A Randomized, Open-Label, Phase III Study of RPR109881 IV Every 3 Weeks Versus Capecitabine (Xeloda) Tablets Twice Daily for 2 Weeks in 3-Week Cycles in Patients With Metastatic Breast Cancer Progressing After Taxanes and Anthracycline Therapy

Trial Profile

A Randomized, Open-Label, Phase III Study of RPR109881 IV Every 3 Weeks Versus Capecitabine (Xeloda) Tablets Twice Daily for 2 Weeks in 3-Week Cycles in Patients With Metastatic Breast Cancer Progressing After Taxanes and Anthracycline Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Capecitabine; Larotaxel
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Aventis Pharmaceuticals
  • Most Recent Events

    • 20 Aug 2008 Official title updated, based on information from ClinicalTrials.gov.
    • 20 Aug 2008 Official title updated, based on information from ClinicalTrials.gov.
    • 20 Aug 2008 Actual end date added (source ClinicalTrials.gov).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top